220 related articles for article (PubMed ID: 21971667)
21. Emerging drugs for chemotherapy-induced emesis.
Navari RM; Province PS
Expert Opin Emerg Drugs; 2006 Mar; 11(1):137-51. PubMed ID: 16503832
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium.
Annemans L; Strens D; Lox E; Petit C; Malonne H
Support Care Cancer; 2008 Aug; 16(8):905-15. PubMed ID: 17965891
[TBL] [Abstract][Full Text] [Related]
23. Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting: A Network Meta-Analysis.
Zhang Y; Yang Y; Zhang Z; Fang W; Kang S; Luo Y; Sheng J; Zhan J; Hong S; Huang Y; Zhou N; Zhao H; Zhang L
J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 27795228
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types.
Kim JE; Jang JS; Kim JW; Sung YL; Cho CH; Lee MA; Kim DJ; Ahn MJ; Lee KY; Sym SJ; Lim MC; Jung H; Cho EK; Min KW
Support Care Cancer; 2017 Mar; 25(3):801-809. PubMed ID: 27826874
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of aprepitant among patients aged 65 and over receiving moderately to highly emetogenic chemotherapy: a meta-analysis of unpublished data from previously published studies.
Chapell R; Aapro MS
J Geriatr Oncol; 2013 Jan; 4(1):78-83. PubMed ID: 24071495
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.
Chanthawong S; Lim YH; Subongkot S; Chan A; Andalusia R; Ahmad Bustamam RS; Chaiyakunapruk N
Support Care Cancer; 2019 Mar; 27(3):1109-1119. PubMed ID: 30112718
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic and preventive antiemetic effect of aprepitant in Japanese patients with thoracic malignancies who truly need it.
Ito S; Tsukiyama I; Ando M; Katakami M; Hamanaka R; Kosaka K; Matsubara A; Nishimura M; Tanaka H; Asai N; Yokoe N; Takahashi A; Baba K; Matsuura K; Yamaguchi E; Kubo A
Support Care Cancer; 2015 Apr; 23(4):905-12. PubMed ID: 25223352
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of aprepitant in patients with advanced or recurrent lung cancer receiving moderately emetogenic chemotherapy.
Uchino J; Hirano R; Tashiro N; Yoshida Y; Ushijima S; Matsumoto T; Ohta K; Nakatomi K; Takayama K; Fujita M; Nakanishi Y; Watanabe K
Asian Pac J Cancer Prev; 2012; 13(8):4187-90. PubMed ID: 23098425
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of fosaprepitant in the prevention of nausea and vomiting following highly emetogenic chemotherapy in Chinese people: A randomized, double-blind, phase III study.
Yang LQ; Sun XC; Qin SK; Cheng Y; Shi JH; Chen ZD; Wang QM; Zhang HL; Hu B; Liu B; Zhang QY; Wu Q; Wang D; Shu YQ; Dong J; Han BH; Wang KM; Dang CX; Li JL; Wang HB; Li BL; Lu JG; Zhang ZH; Chen YX
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28393417
[TBL] [Abstract][Full Text] [Related]
30. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant.
Grote T; Hajdenberg J; Cartmell A; Ferguson S; Ginkel A; Charu V
J Support Oncol; 2006 Sep; 4(8):403-8. PubMed ID: 17004515
[TBL] [Abstract][Full Text] [Related]
31. Use of dexamethasone and a 5-HT3 receptor antagonist with or without aprepitant to prevent chemotherapy-induced nausea and vomiting among patients with lung cancer who are treated with platinum-based chemotherapy: a systematic review and meta-analysis of randomized controlled trials.
He M; Xu R; Liu M; Zhang Y; Yi F; Wei Y; Liu Q; Zhang W
Ann Palliat Med; 2021 Apr; 10(4):4308-4319. PubMed ID: 33894731
[TBL] [Abstract][Full Text] [Related]
32. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Carides G; Elmer M; Schmidt C; Evans JK; Horgan KJ
J Clin Oncol; 2003 Nov; 21(22):4105-11. PubMed ID: 14559891
[TBL] [Abstract][Full Text] [Related]
33. Fosaprepitant Dimeglumine: A Review in the Prevention of Nausea and Vomiting Associated with Chemotherapy.
Garnock-Jones KP
Drugs; 2016 Sep; 76(14):1365-72. PubMed ID: 27510503
[TBL] [Abstract][Full Text] [Related]
34. Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy.
Olver IN; Grimison P; Chatfield M; Stockler MR; Toner GC; Gebski V; Harrup R; Underhill C; Kichenadasse G; Singhal N; Davis ID; Boland A; McDonald A; Thomson D;
Support Care Cancer; 2013 Jun; 21(6):1561-8. PubMed ID: 23274926
[TBL] [Abstract][Full Text] [Related]
35. A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC).
Zhang L; Lu S; Feng J; Dechaphunkul A; Chang J; Wang D; Chessari S; Lanzarotti C; Jordan K; Aapro M
Ann Oncol; 2018 Feb; 29(2):452-458. PubMed ID: 29092012
[TBL] [Abstract][Full Text] [Related]
36. Comparative Cost-utility Analysis Between Aprepitant- and Fosaprepitant-containing Regimens To Prevent Chemotherapy-induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy in Japan.
Kashiwa M; Matsushita R
Clin Ther; 2019 May; 41(5):929-942. PubMed ID: 31036286
[TBL] [Abstract][Full Text] [Related]
37. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.
Hesketh PJ; Grunberg SM; Gralla RJ; Warr DG; Roila F; de Wit R; Chawla SP; Carides AD; Ianus J; Elmer ME; Evans JK; Beck K; Reines S; Horgan KJ;
J Clin Oncol; 2003 Nov; 21(22):4112-9. PubMed ID: 14559886
[TBL] [Abstract][Full Text] [Related]
38. Aprepitant as salvage therapy in patients with chemotherapy-induced nausea and emesis refractory to prophylaxis with 5-HT(3) antagonists and dexamethasone.
Oechsle K; Müller MR; Hartmann JT; Kanz L; Bokemeyer C
Onkologie; 2006 Dec; 29(12):557-61. PubMed ID: 17202825
[TBL] [Abstract][Full Text] [Related]
39. Addition of Aprepitant (Emend®) to Standard Antiemetic Regimen Continued for 7 Days after Chemotherapy for Stem Cell Transplantation Provides Significant Reduction of Vomiting.
Svanberg A; Birgegård G
Oncology; 2015; 89(1):31-6. PubMed ID: 25659986
[TBL] [Abstract][Full Text] [Related]
40. Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial.
Hu Z; Cheng Y; Zhang H; Zhou C; Han B; Zhang Y; Huang C; Chang J; Song X; Liang J; Liang H; Bai C; Yu S; Chen J; Wang J; Pan H; Chitkara DK; Hille DA; Zhang L
Support Care Cancer; 2014 Apr; 22(4):979-87. PubMed ID: 24276953
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
